Science News
from research organizations

A Winning Combination For The Treatment Of Cancer

Date:
August 21, 2007
Source:
Journal of Clinical Investigation
Summary:
The immune system does not destroy tumors even though they express molecules that should activate immune cells. The immune system is therefore said to be tolerant of the tumors. Several molecules and cell types have been implicated in the induction of immune system tolerance to tumors, including, in mice, a small population of immune cells known as plasmacytoid dendritic cells and that are isolated from the lymph nodes that drain the site of the tumor.
Share:
FULL STORY

The immune system does not destroy tumors even though they express molecules that should activate immune cells.

The immune system is therefore said to be tolerant of the tumors. Several molecules and cell types have been implicated in the induction of immune system tolerance to tumors, including, in mice, a small population of immune cells known as plasmacytoid dendritic cells (pDCs) that produce the enzyme indoleamine 2,3-dioxygenase (IDO) and that are isolated from the lymph nodes that drain the site of the tumor.

Now, researchers from the Medical College of Georgia, Augusta, have identified how these mouse IDO-expressing pDCs induce tumor-specific immune tolerance.

In the study, which appears online on August 16 in advance of publication in the September print issue of the Journal of Clinical Investigation, David Munn and colleagues found that mouse IDO-expressing pDCs from tumor-draining lymph nodes directly activate the suppressive function of a population of regulatory immune cells characterized as CD4+CD25+Foxp3+ and known as Tregs.

Suppression by Tregs activated by IDO-expressing pDCs was mediated by interactions between programmed cell death 1 (PD1) and its ligands. This mechanism of suppression is distinct from that used by Tregs activated by other stimuli. Importantly, immune suppression in tumor-draining lymph nodes was abrogated by treating mice with both a chemotherapeutic drug and a chemical inhibitor of IDO, but not either agent alone, leading the authors to suggest that combining IDO inhibitors with chemotherapeutic agents might improve the efficacy of chemotherapeutics in individuals with cancer.

Article: Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3,-dioxygenase


Story Source:

Materials provided by Journal of Clinical Investigation. Note: Content may be edited for style and length.


Cite This Page:

Journal of Clinical Investigation. "A Winning Combination For The Treatment Of Cancer." ScienceDaily. ScienceDaily, 21 August 2007. <www.sciencedaily.com/releases/2007/08/070818085107.htm>.
Journal of Clinical Investigation. (2007, August 21). A Winning Combination For The Treatment Of Cancer. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2007/08/070818085107.htm
Journal of Clinical Investigation. "A Winning Combination For The Treatment Of Cancer." ScienceDaily. www.sciencedaily.com/releases/2007/08/070818085107.htm (accessed May 23, 2017).

RELATED STORIES